PDUFA meeting
This article was originally published in The Tan Sheet
Executive Summary
FDA to hear stakeholder testimony Dec. 7 in Bethesda, Md., on what aspects of user fee program should be retained or changed and whether program should allow use of user fee funding to monitor post-approval drug safety. Agency also seeks input on how it can ensure PDUFA goals are met in wake of continued funding shortfalls and whether there should be flexibility in setting user fees to cover increased program costs. PDUFA legislative authority sunsets in September 2002; FDA held a similar public meeting last year (1"The Tan Sheet" Sept. 25, 2000, p. 8)...
You may also be interested in...
GPhA Still Wary Of Generic User Fees; Issue Tied To Waxman/Hatch Reform
Generic drug user fees should be considered only in the context of changes to Waxman/Hatch-related barriers to generic entry, the Generic Pharmaceutical Association told FDA at a Sept. 15 meeting on the Prescription Drug User Fee Act reauthorization process.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.